Antitope Ltd, UK. Announces EpiScreen Collaboration with Hanmi Pharmaceutical Company Ltd, Korea.

24th September 2008 - Antitope Ltd. today announced a research collaboration with leading Korean company Hanmi Pharmaceutical Company Limited ("Hanmi") where Antitope will apply EpiScreenTM technology to profile the immunogenicity of therapeutic proteins.

"We are delighted to be working with Hanmi who are recognised as leaders in the development of new generation biopharmaceuticals," said Dr Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited. "We look forward to assisting Hanmi in selecting therapeutic leads with a low risk of immunogenicity ."

About Antitope

Antitope Ltd. is a Cambridge UK-based biotechnology company specializing in immunogenicity testing and the engineering of therapeutic antibodies/proteins to reduce immunogenicity. Antitope's proprietary EpiScreenTM technology uses human T cells to measure the immunogenicity potential of biopharmaceuticals. Antitope's Composite Human AntibodyTM and Composite ProteinTM technologies deliver novel therapeutic antibodies and proteins with low immunogenicity potential through the avoidance of T cell epitopes. Antitope is a privately-held company and has established multiple commercial relationships with leading biotechnology and pharmaceutical companies. For further information on Antitope visit http://www.antitope.co.uk/.

About Hanmi

Hanmi has been the leader in Korean pharmaceutical industry as number one in drug prescription and number two in the total revenue in Korean pharmaceutical market. Hanmi's R&D strategy is to develop its own new products targeting the global market. Hanmi's LAPSCOVERY (Long-acting protein/peptide discovery) and ORASCOVERY (Oral drug discovery) are the core of Hanmi's proprietary new drug product development platform technologies. For further information on Hanmi visit http://www.hanmipharm.com/

For further information contact:

Dr Neil Butt

Business Development Director

Antitope

Tel: +44 (0)1223 496190

Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it